

# Product information

Information about other products is available at: [www.demeditec.com](http://www.demeditec.com)



## Instruction for use

# GBM Ab ELISA

Enzyme Immunoassay for Quantitative Determination of IgG Auto-antibodies to GBM in human serum or plasma



DE7130



96 Tests

## PRINCIPLE OF THE TEST

Highly purified GBM is bound to microwells. Antibodies against the coated antigen, if present in diluted patient sample, bind to the respective antigen. Washing of the microwells removes unbound unspecific serum and plasma components. Horseradish peroxidase (HRP) conjugated anti-human antibodies immunologically detect the bound patient antibodies forming a conjugate/antibody/antigen complex. Washing of the microwells removes unbound conjugate. An enzyme substrate in the presence of bound conjugate hydrolyzes to form a blue colour. The addition of an acid stops the reaction forming a yellow end-product. The intensity of this yellow colour is measured photometrically at 450 nm. The amount of colour is directly proportional to the concentration of antibodies present in the original sample.

## SUMMARY AND EXPLANATION OF THE TEST

Primarily, Goodpasture syndrome is an autoimmune disorder of the kidneys. Ernest Goodpasture, an American pathologist was the first in 1919 who described the coexistence of a fatal lung hemorrhage coming along with proliferative glomerulonephritis in a young man. The syndrome is now considered as an autoimmune disorder consisting of the triad of glomerulonephritis, lung hemorrhage and anti-glomerular basement antibodies formation.

The incidence of the Goodpasture syndrome is about 0.5 to 1 cases per million inhabitants per year. Patients in the third and seventh decade are mainly affected. Goodpasture syndrome is a medical emergency with a case fatality rate of 75 to 90 % due to kidney and respiratory insufficiency, if not treated. Histological, the disorder is characterized by continuous linear deposition of immunoglobulins along the glomerular basement membrane (GBM), demonstrable by direct immunofluorescence on kidney biopsies. Nowadays, the determination of circulating autoantibodies against the C-terminal end of the  $\alpha$ -3 chain of type IV collagen is considered the diagnostic criterion.

Basement membranes form an anatomical barrier wherever epithelia meet connective tissue. Type IV collagen that is only found in GBM forms a matrix in which additional molecules (e.g. Laminin, Entactin) are integrated. Three out of six alpha-chains (polypeptides with more than 1,650 amino acids) form a triple helix and characterize the structural subunits of type IV collagen. All C-terminal ends of the alpha-chains form a globular domain that can be dissolved from the triple helix by treatment with bacterial collagenase.

The reactivity of Goodpasture specific anti-GBM autoantibodies is directed against the 29 kDa NC1 domain of the alpha-3 chain of type IV collagen of GBM. After the target antigen has been entirely characterized nowadays the triad of glomerulonephritis, lung hemorrhage and the anti-bodies against the  $\alpha$ -3 chain of type IV collagen of GBM are the essential elements of diagnosis of Goodpasture syndrome. ELISA test systems provided with the corresponding pure antigen exhibit sensitivities and specificities of about 98 to 99%.

## CONTENTS OF THE KIT

Sufficient for 96 determinations

**1 One divisible microplate** consisting of 12 modules of 8 wells each. Ready to use.

**5x 1.5 ml Calibrator A-E** (0, 20, 40, 80, 200 U/ml), containing serum/buffer matrix (PBS, BSA, detergent,  $\text{NaN}_3$  0.09%), yellow. Ready to use.

**2x 1.5 ml Control positive (1) and negative (2)**, containing GBM antibodies in a serum/buffer matrix (PBS, BSA, detergent,  $\text{NaN}_3$  0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.

**20 ml Sample Buffer P**, containing PBS, BSA, detergent, preservative  $\text{NaN}_3$  0.09%, yellow, 5x conc.

**15 ml Enzyme Conjugate** containing anti-human IgG antibodies, HRP labelled; PBS, BSA, detergent, preservative ProClin 300 0.05%, light red. Ready to use.

**15 ml TMB Substrate**; containing 3,3', 5,5'- Tetramethylbenzidin, colorless. Ready to use.

**15 ml Stop Solution**; contains acid. Ready to use.

**20 ml Wash Solution**, containing Tris, detergent, preservative  $\text{NaN}_3$  0.09%; 50 x conc.

**1 Instruction for Use**

**1 Certificate of Analysis**

## **MATERIALS REQUIRED**

- Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
- Data reduction software
- Multi-channel dispenser or repeatable pipette for 100 µl
- Vortex mixer
- Pipettes for 10 µl, 100 µl and 1000 µl
- Laboratory timing device
- Distilled or deionised water
- Measuring cylinder for 1000 ml and 100 ml
- Plastic container for storage of the wash solution

This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system. Detailed information is provided upon request.

## **SPECIMEN COLLECTION, STORAGE AND HANDLING**

- Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8 °C for up to five days or stored at -20 °C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- Testing of heat-inactivated sera is not recommended.

## **STORAGE AND STABILITY**

- Store test kit at 2-8 °C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store microplate sealed and desiccated in the clip bag provided.
- Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash Solution and Sample Buffer are stable for at least 30 days when stored at 2-8 °C. We recommend consumption on the same day.

## **PROCEDURAL NOTES**

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots and products.
- All materials must be at room temperature (20-28 °C) prior to use.
- Prepare all reagents and samples. Once started, perform the test without interruption.
- Double determinations may be done. By this means pipetting errors may become obvious.
- Perform the assay steps only in the order indicated.
- Always use fresh sample dilutions.
- Pipette all reagents and samples into the bottom of the wells.
- To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
- Wash microwells thoroughly and remove the last droplets of Wash Solution.
- All incubation steps must be accurately timed.
- Do not re-use microplate wells.

## WARNINGS AND PRECAUTIONS

- All reagents of this kit are intended for professional in vitro diagnostic use only.
  - Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
  - Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
  - Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
  - Stop solution contains acid, classification is non-hazardous. Avoid contact with skin.
  - Calibrators, Controls, sample buffer and Wash Solution contain sodium azide (NaN<sub>3</sub>) 0.09% as preservative. This concentration is classified as non-hazardous.
  - Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.
  - During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:
  - First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin, wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running water for at least 10 minutes. Get medical attention if necessary.
  - Personal precautions, protective equipment and emergency procedures:
  - Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.
  - Exposure controls / personal protection: Wear protective gloves of nitrile rubber or natural latex. Wear protective glasses. Used according to intended use no dangerous reactions known.
  - Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
  - For disposal of laboratory waste the national or regional legislation has to be observed.
- Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

## PREPARATION OF REAGENTS

### Wash Solution

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

### Sample Buffer

Sample Buffer P: Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 ml.

### Preparation of samples

Dilute all patient samples 1:50 with sample buffer prior to use in the assay: combine 20 µl of sample with 980 µl of diluted sample buffer in a polystyrene tube. Mix well. Note: Calibrators / Controls are ready to use and need no dilution.

## TEST PROCEDURE

Prepare enough microplate modules for all calibrators / controls and patient samples.

1. Pipette 100 µl of calibrators, controls and prediluted patient samples into the wells.
2. Incubate for 30 minutes at room temperature (20-28 °C).
3. Discard the contents of the microwells and wash 3 times with 300 µl of wash solution.
4. Dispense 100 µl of enzyme conjugate into each well.
5. Incubate for 15 minutes at room temperature.
6. Discard the contents of the microwells and wash 3 times with 300 µl of wash solution.
7. Dispense 100 µl of TMB substrate solution into each well.
8. Incubate for 15 minutes at room temperature
9. Add 100 µl of stop solution to each well of the modules
10. Incubate for 5 minutes at room temperature.
11. Read the optical density at 450 nm (reference 600-690nm) and calculate the results. The developed colour is stable for at least 30 minutes. Read during this time.

Example for a pipetting scheme:

	1	2	3	4	5	6	7	8	9	10	11	12
A	A	P2										
B	B	P3										
C	C											
D	D											
E	E											
F	C+											
G	C-											
H	P1											

P1, ... patient sample A-E calibrators C+, C- controls

## VALIDATION

Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit. If these quality control criteria are not met the assay run is invalid and should be repeated.

## CALCULATION OF RESULTS

For quantitative results plot the optical density of each calibrator versus the calibrator concentration to create a calibration curve. The concentration of patient samples may then be estimated from the calibration curve by interpolation. Using data reduction software a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

## PERFORMANCE CHARACTERISTICS

### Calibration

This assay system is calibrated in relative arbitrary units, since no international reference preparation is available for this assay.

### Measuring range

The calculation range of this ELISA assay is 0 - 200 U/ml

### Expected values

In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay: Cut-off 20 U/ml

### Interpretation of results

Negative: < 20 U/ml

Positive: ≥ 20 U/ml

**Linearity**

Patient samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay and the upper / lower end of linearity. Activity for each dilution was calculated from the calibration curve using a 4-Parameter-Fit with lin-log coordinates.

Sample	Dilution	Observed U/ml	Expected U/ml	O/E [%]
1	1:100	175.7	175.7	100
.	1:200	89.0	87.9	101
.	1:400	43.2	43.9	98
.	1:800	21.8	22.0	99
.	1:1600	10.1	11.0	92
2	1:100	189.2	189.2	100
.	1:200	93.5	94.6	99
.	1:400	45.0	47.3	95
.	1:800	22.6	23.7	95
.	1:1600	11.0	11.8	93

**Limit of detection**

Functional sensitivity was determined to be: 1 U/ml

**Interfering substances**

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparin). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

**Reproducibility**

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 6 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

Intra-Assay		
Sample	Mean U/ml	CV %
1	15.6	5.3
2	85.8	5.4
3	143.4	5.7

Inter-Assay		
Sample	Mean U/ml	CV %
1	14.2	6.4
2	90.1	5.4
3	154.4	5.8

**Study results**

Study population	N	n Pos	%
Goodpastures syndrome	20	20	100.0
Connective tissue disease	20	1	5.0
Autoimmune vasculitis	20	0	0.0
Normal human sera	100	0	0.0

		Clinical Diagnosis		
		Pos	Neg	
Pos	20	1		
Neg	0	139		
	20	140	160	

Sensitivity:	100.0 %
Specificity:	99.3 %
Overall agreement:	99.4 %

## LIMITATIONS OF THE PROCEDURE









This assay is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated concerning the entire clinical picture of the patient. Also every decision for therapy should be taken individually.











The above pathological and normal reference ranges for antibodies in patient samples should be regarded as recommendations only. Each laboratory should establish its own ranges according to ISO 15189 or other applicable laboratory guidelines.

## REFERENCES

1. Bolton, W.K. Goodpasture's syndrome. *Kidney Int.*, Vol. 50, 1753-1766, 1996
2. Daly, C., Conlon, P. J., Medwar, W., Walshe, J. J. Characteristics and outcome of anti-glomerular basement membrane disease: a single centre experience. *Ren. Fail.*, Vol. 18, 105-112, 1996
3. Goodpasture, E. W. The significance of certain pulmonary lesions to the etiology of influenza. *Am. J. Med. Sci.*, Vol.158, 864-870, 1919
4. Hellmark, T., Segelmark, M., Bygren, P., Wieslander, J. Glomerular basement membrane autoantibodies. in: Peter, J. B., Shoenfeld, Y. (Hrsg.), *Autoantibodies*, S. 291-298, 1996
5. Hudson, B.G., Reeders, S. T., Tryggvason, K. Type IV collagen: structure, gene organization, and role in human diseases. *J. Biol. Chem.*, Vol. 268, 26033-26036, 1993
6. Hudson, B. G., Wieslander, J., Wisdom, B. J., Noelken, M. E. Goodpasture syndrome: Molecular architecture and function of basement membrane antigen. *Lab. Invest.*, Vol. 61, 256-269, 1989
7. Kalluri, R., Gattone, V. H., Noelken, M. E., Hudson, B. G. The alpha-3 chain of type IV collagen induces autoimmune Goodpasture syndrome. *PNAS*, Vol.91, 6201-6205, 1994
8. Kalluri, R., Melendez, E., Rumpf, K. W., Sattler, K., et al. Specificity of circulating and tissue bound autoantibodies in Goodpasture syndrome *Proc. Assoc. Am. Physicians*, Vol. 108, 134-139, 1996
9. Saxena, R., Sturfelt, G., Nived, O., Wieslander, J. Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders. *Ann. Rheum. Dis.*, Vol. 53, 659-665, 1994
10. Wieslander, J., Bygren, P., Heinegard, D. Isolation of the specific glomerular basement membrane antigen involved in Goodpasture syndrome. *Proc. Natl. Acad. Sci. USA*, Vol. 81, 1544-1548, 1984a
11. Wieslander, J., Barr, J.F., Butkowski, R. J., Edwards, S. J. et al. Goodpasture antigen of the glomerular basement membrane: localization to noncollagenous regions of type IV collagen. *PNAS*, Vol. 81, 3838-3842, 1984b
12. Schultz H: From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI). *Autoimmun.Rev* 2007, 6:223-227.

## SYMBOLS USED WITH DEMEDITEC ASSAYS

Symbol	English	Deutsch	Français	Español	Italiano
	Consult instructions for use	Gebrauchsanweisung beachten	Consulter les instructions d'utilisation	Consulte las instrucciones de uso	Consultare le istruzioni per l'uso
	European Conformity	CE-Konformitätskennzeichnung	Conformité aux normes européennes	Conformidad europea	Conformità europea
	In vitro diagnostic device	In-vitro-Diagnostikum	Usage Diagnostic in vitro	Para uso Diagnóstico in vitro	Per uso Diagnostica in vitro
	For research use only	Nur für Forschungszwecke	Seulement dans le cadre de recherches	Sólo para uso en investigación	Solo a scopo di ricerca
	Catalogue number	Katalog-Nr.	Numéro de catalogue	Número de catálogo	Numero di Catalogo
	Lot. No. / Batch code	Chargen-Nr.	Numéro de lot	Número de lote	Numero di lotto
	Contains sufficient for <n> tests/	Ausreichend für "n" Ansätze	Contenu suffisant pour "n" tests	Contenido suficiente para <n> ensayos	Contenuto sufficiente per "n" saggi
	Storage Temperature	Lagerungstemperatur	Température de conservation	Temperatura de conservación	Temperatura di conservazione
	Expiration Date	Mindesthaltbarkeitsdatum	Date limite d'utilisation	Fecha de caducidad	Data di scadenza
	Legal Manufacturer	Hersteller	Fabricant	Fabricante	Fabbricante
Distributed by	Distributor	Vertreiber	Distributeur	Distribuidor	Distributore
Content	Content	Inhalt	Conditionnement	Contenido	Contenuto
Volume/No.	Volume / No.	Volumen/Anzahl	Volume/Quantité	Volumen/Número	Volume/Quantità

Symbol	Portugues	Dansk	Svenska	Ελληνικά
	Consulte as instruções de utilização	Se brugsanvisning	Se bruksanvisningen	Εγχειρίδιο χρήστη
	Conformidade com as normas europeias	Europaeisk overensstemmelse	Europeisk överensstämmelse	Ευρωπαϊκή Συμμόρφωση
	Diagnóstico in vitro	In vitro diagnostik	Diagnostik in vitro	in vitro διαγνωστικό
				
	Catálogo n.º	Katalognummer	Katalog nummer	Αριθμός καταλόγου
	No do lote	Lot nummer	Batch-nummer	Αριθμός Παρτίδος
		Indeholder tilstrækkeligt til "n" test	Innehåller tillräckligt till "n" tester	Περιεχόμενο επαρκές για «n» εξετάσεις
	Temperatura de conservação	Opbevaringstemperatur	Förvaringstemperatur	Θερμοκρασία αποθήκευσης
	Prazo de validade	Udløbsdato	Bäst före datum	Ημερομηνία λήξης
	Fabricante	Producent	Tillverkare	Κατασκευαστής
Distributed by				
Content	Conteúdo	Indhold	Innehåll	Περιεχόμενο
Volume/No.	Volume/Número	Volumen/antal	Volym/antal	Όγκος/αριθ..